By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Omeros Corporation 

1420 Fifth Avenue
Suite 2675
Seattle  Washington  98101  U.S.A.
Phone: 206-623-4688 Fax: 206-264-7856



Company News
Data From Omeros (OMER)’ OMS721 Phase 2 Clinical Trial In Patients With Stem Cell Transplant-Associated TMA To Be Presented At International Transplant Conference 12/7/2016 11:11:02 AM
Omeros (OMER) Extending Compassionate Use For Pediatric Patient No Longer Requiring Dialysis After OMS721 Treatment 12/6/2016 9:18:13 AM
Omeros (OMER)’ Proprietary Orphan GPCR Program Delivers New Target And Approach In Cancer Immunotherapy 12/5/2016 11:24:10 AM
Omeros (OMER) Release: International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury 11/30/2016 10:59:42 AM
Omeros (OMER) Announces Successful Outcome Of OMIDRIA Pediatric Cataract Trial 11/21/2016 10:59:46 AM
Omeros (OMER) Reports Third Quarter 2016 Financial Results 11/10/2016 3:10:32 PM
Single Dose Of Omeros (OMER)’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade Of The Alternative Pathway 11/10/2016 2:38:34 PM
Omeros (OMER) To Announce Third Quarter 2016 Financial Results On November 9, 2016 11/7/2016 10:24:44 AM
Omeros (OMER) Announces Completion Of Initial Funding Under $125 Million Credit Facility 11/4/2016 10:20:42 AM
Omeros (OMER) Files Orphan Drug Application For OMS721 In Immunoglobulin A Nephropathy 11/3/2016 11:22:31 AM